We've changed the way you complete courses

In response to user feedback we have simplified the way courses can be completed.

Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.

Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.

Once you have completed all of the topics in a module an assessment will be provided for you.

Complete all the assessments to finish the course.

Thanks, I've got it! X

Select image for larger view
When talking to clinicians, they will all agree that type 1 diabetes is a heterogeneous disease. Some people have just type 1 diabetes, others have multiple autoimmune diseases, where type 1 diabetes is linked to graves disease, for instance, or to alopecia. In some individuals, the disease presents very early on. In others, it presents only later in life. Some individuals have only autoantibodies against one type of antigen of the beta cell, like insulin. Others have a myriad of autoantibodies. Some have good clinical control, as expressed by HbA1c, others have suboptimal HbA1c. And, also, when looking at the functional beta cell mass that is left in individuals with type 1 diabetes it is obvious that some are able to preserve beta cell mass for many years and, finally, complications and the risk for complications, is very different from individual to individual. So, just clinically, type 1 diabetes is a very heterogeneous disease. And in the response to immune modulatory therapy there also seems to be heterogeneity.
Play the audio to learn more